This is a prospective observational study in which patients with untreated retroperitoneal sarcoma will have Magnetic Resonance Imaging (MRI) prior to surgery. In addition, patients who will be undergoing pre-operative radiotherapy will have an additional MRI scan at two weeks post radiotherapy. For both groups, the magnetic resonance images will be correlated with tumour pathology. The study hypothesis is that Magnetic Resonance Imaging will provide a more accurate assessment of tumour volume and local staging than CT and will identify areas of altered oxygenation, cellularity and perfusion which change in response to radiotherapy before tumour shrinkage occurs.
Study Type
OBSERVATIONAL
Enrollment
32
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom
Prediction, by MRI, of early response to radiotherapy prior to tumour shrinkage
Changes in volume, maximum axial diameter, ADC, F, D, D\*, T2, R2\* and enhancing fraction from baseline to post radiotherapy will be presented. A paired T-test (or Wilcoxon Signed Rank Test) may be used to test the difference between baseline and post radiotherapy. Differences in these values will be presented for responders and non-responders, which will be tested by independent T-test. Response will be determined by tumour size, enhancing fraction and histopathological evidence of response.
Time frame: 2-4 weeks
To determine the reproducibility of multi-parametric MRI measurements within tumour regions of interest in patients with retroperitoneal sarcoma.
Reproducibility of the parameter ADC-Apparent Diffusion Coefficient (also F, D, D\*, T2 and R2\* values)between the two scans at baseline (within 7 days of each other)will be assessed using the Bland Altman method.
Time frame: 1-7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.